Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 3, 2006, Pages 669-677

  Merrick, Gregory S ^a   Butler, Wayne M ^a   Wallner, Kent E ^b   Galbreath, Robert W ^a,c   Allen, Zachariah A ^a   Adamovich, Edward ^d  

^a WHEELING JESUIT UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ohio University Eastern   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Brachytherapy; Prostate cancer; Survival

Indexed keywords

BIOCHEMISTRY; BIOPSY; CARDIOVASCULAR SURGERY; DISEASE CONTROL; DOSIMETRY; REGRESSION ANALYSIS; TUMORS;

ANDROGEN-DEPRIVATION THERAPY (ADT); BRACHYTHERAPY; PROSTATE CANCER; SURVIVAL;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; METASTASIS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SECOND CANCER; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TOBACCO; TREATMENT DURATION;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CAUSE OF DEATH; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SMOKING; SURVIVAL RATE;

EID: 33646948287     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.01.030     Document Type: Article

References (22)

1. Merrick G.S., Wallner K.E., and Butler W.M. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 169 (2003) 1643-1652
2. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen dep-rivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
3. Merrick G.S., Wallner K.E., and Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology 62 (2003) 786-792
4. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
5. 125I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
6. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer 97 (2003) 979-983
7. Lee L., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444-452
8. Merrick G.S. Prostate brachytherapy. The shrinking role of hormonal therapy. Brachytherapy 2 (2003) 2-4
9. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18 (2000) 1187-1192
10. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
11. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy. Rationale, design and evaluation. Tech Urol 6 (2000) 78-84
12. Merrick G.S., Butler W.M., Dorsey A.T., et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 46 (2000) 215-220
13. Merrick G.S., Butler W.M., Dorsey A.T., et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 7 (2001) 233-240
14. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) E178-E189
15. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources. Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
16. Beyer D., Nath R., Butler W., et al. American brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 47 (2000) 273-275
17. 125I transperineal prostate seed implants on commercial treatment planning systems. Int J Radiat Oncol Biol Phys 37 (1997) 737-741
18. Amling C.L., Bergstralh E.J., Blute M.J., et al. Defining prostate specific antigen progression after radical prostatectomy. What is the most appropriate cutpoint?. J Urol 165 (2001) 1146-1151
19. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 64 (2004) 754-759
20. Hinerman-Mulroy A., Merrick G.S., Butler W.M., et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367-1382
21. Kollmeier M.A., Stock R.G., and Stone N.N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up. Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
22. Tyrrell C.J., Payne H., See W.A., et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localized or locally advanced prostate cancer. Results from the randomized Early Prostate Cancer Programme. Radiother Oncol 76 (2005) 4-10